Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation

MLA

Wayne A. Ray, et al. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. Dec. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....dee963d0693a37031ded9ddd9de0aeb8&authtype=sso&custid=ns315887.

APA

Wayne A. Ray, Cecilia P. Chung, C. Michael Stein, Walter Smalley, Eli Zimmerman, William D. Dupont, Adriana M. Hung, James R. Daugherty, Alyson Dickson, & Katherine T. Murray. (2021). Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.

Chicago

Wayne A. Ray, Cecilia P. Chung, C. Michael Stein, Walter Smalley, Eli Zimmerman, William D. Dupont, Adriana M. Hung, James R. Daugherty, Alyson Dickson, and Katherine T. Murray. 2021. “Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation,” December. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....dee963d0693a37031ded9ddd9de0aeb8&authtype=sso&custid=ns315887.